Karyopharm Therapeutics Inc Stock Price, News & Analysis

Karyopharm Therapeutics (Nasdaq: KPTI) announced CEO Michael Kauffman's participation in upcoming investor conferences: Baird's 2020 Global Healthcare Conference on September 9 at 10:15 AM ET and Morgan Stanley's 18th Annual Global Healthcare Conference on September 15 at 5:00 PM ET. The events will feature live webcasts accessible via the company's investor section, with replays available for 90 days. Karyopharm is known for its innovative cancer therapies, particularly its lead drug, XPOVIO, which has received multiple FDA approvals for various cancer treatments.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced stock options for 29,600 shares granted to seven new employees as part of a recruitment incentive, with an exercise price of $15.21 per share. The options vest over four years, with 25% vesting on the one-year anniversary of employment. Notably, these options will be immediately exercisable if employment is terminated for 'good reason' or without 'cause' within a year following a change in control. Karyopharm focuses on innovative cancer therapies, including its lead compound, XPOVIO, which has received FDA approval for multiple myeloma and lymphoma.

Karyopharm Therapeutics (Nasdaq: KPTI) has appointed Christy J. Oliger to its Board of Directors. Oliger, previously the Senior VP of Genentech's Oncology Business Unit, brings over 25 years of experience in the biopharmaceutical sector. Her expertise is expected to aid in the development and commercialization of Karyopharm's lead product, XPOVIO, which is already FDA-approved for multiple indications. CEO Michael G. Kauffman emphasized her strategic value for expanding XPOVIO's reach to new patient populations. Oliger aims to contribute to the company's growth and enhance its impact on cancer treatment.

Karyopharm Therapeutics (KPTI) reported second-quarter 2020 financial results, achieving record sales of $18.6 million for XPOVIO despite ongoing COVID-19 challenges. The FDA granted accelerated approval for XPOVIO to treat relapsed DLBCL, marking it as the only oral agent for this indication. The company announced a significant 16% sales increase from Q1 2020 and reported a 47% improvement in progression-free survival in a key clinical study. However, Karyopharm faced a net loss of $46.4 million, largely influenced by increased R&D expenses.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced on August 3, 2020, the grant of stock options to purchase 27,300 shares of its common stock to three newly-hired employees, effective July 31, 2020. The options have an exercise price of $16.05 per share, equivalent to the closing price on the grant date. These stock options will vest over four years, with 25% vesting on the first anniversary of employment. In case of a change in control event, employees can fully exercise options if terminated for good reason or without cause.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) will announce its second quarter 2020 financial results on August 4, 2020. A conference call is scheduled for 8:30 a.m. ET the same day, allowing investors to discuss the results and company updates. The company is known for its innovation in pharmaceutical development, particularly its lead compound, XPOVIO®, which has FDA approval for treating multiple myeloma and diffuse large B-cell lymphoma. Investors can access the live audio webcast through Karyopharm's [Investor section](http://investors.karyopharm.com/events-presentations).

Karyopharm Therapeutics (Nasdaq: KPTI) announced that the FDA has accepted its supplemental New Drug Application (sNDA) for XPOVIO (selinexor) as a treatment for multiple myeloma after at least one prior line of therapy. The FDA decision is expected by the end of Q1 2021. XPOVIO, already approved for penta-refractory multiple myeloma and relapsed diffuse large B-cell lymphoma, aims to broaden its patient base. Karyopharm intends to submit a Marketing Authorization Application to the European Medicines Agency for this indication.

Karyopharm Therapeutics (Nasdaq: KPTI) announced a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to advance XPOVIO (selinexor), a first-in-class oral cancer treatment. The partnership aims to explore XPOVIO's efficacy across various cancer types, supported by promising anti-tumor activity from previous studies. Currently approved for relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma, XPOVIO has a supplemental FDA application for expanded treatment indications. Karyopharm is dedicated to addressing significant unmet medical needs in oncology.

Karyopharm Therapeutics (Nasdaq: KPTI) reported preliminary unaudited net product sales of approximately $18.5 million for its oral cancer treatment XPOVIO in Q2 2020, marking a 15% increase from Q1 2020, the highest quarterly sales since its launch in July 2019. Despite challenges from the COVID-19 pandemic, demand from healthcare providers remains strong. The FDA recently granted accelerated approval for XPOVIO in treating relapsed or refractory diffuse large B-cell lymphoma, following promising Phase 3 study results for multiple myeloma. Full financial results will be announced in August.